that can change lives.

Genomic solutions in reproductive and genetic health.

Empowering informed choices

Your committed partner across the care continuum.

Your committed partner across the care continuum.

Empowering informed reproductive choices. Improving inherited condition screening.

As a leader in innovative genomics technologies, Illumina is now your trusted partner for reliable

answers along the reproductive and genetic health care continuum. Breakthrough products

from both BlueGnome and Verinata are now fully integrated into our portfolio. These additions

expand our ability to serve the needs of clinical laboratories, healthcare professionals, and

patients. Our next-generation sequencing (NGS) and microarray technologies deliver reliable

information that can guide choices and transform lives.

Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD)

Improves in vitro fertilization (IVF) success rates by optimizing embryo selection.

PGD can screen embryos when there is a risk of severe genetic disorders being

inherited from parents.

Cytogenetics

Identifies chromosomal aberrations responsible for genetic conditions that

can cause developmental delay and/or congenital abnormalities.

Noninvasive Prenatal Testing (NIPT)

Early, safe, and reliable screening test delivers answers about the

chromosomal status of a developing fetus—minimizing procedure-related

risks from invasive tests.

Inherited Condition Screening

Helps detect carrier status, aids cystic fibrosis diagnosis, and

facilitates research into the potential causes of undiagnosed

inherited conditions.

Changing reproductive destinies by optimizing embryo selection.

PGS—the new standard of success in IVF.

While IVF has improved the treatment of infertility, its overall success rate remains low.1

Embryos with aneuploidy represent a major reason for IVF failure—causing problems with

implantation or resulting in miscarriage within the first trimester.2,3

PGS is an effective method to screen for euploid embryos prior to implantation to significantly

improve IVF success rates.4

The PGS advantage

• Increased implantation rates—regardless of maternal age5,6

• Lower risk of miscarriage5,7

• Increased rates of ongoing pregnancy and live births4,5,7

• Reduced chance of offspring with aneuploidy8

What’s more, PGS can shorten the time needed to achieve success—reducing the number and

cost of unproductive IVF cycles. PGS also empowers infertility experts to use single embryo

transfers as a way of reducing the incidence of multiple births, which can be both complicated

and costly, especially in women of advanced maternal age.4,5,7 With PGS, the overall result may

be greater patient satisfaction and higher referral rates to IVF centers that routinely offer this

option to their prospective parents.

Access a proven PGS portfolio

• 24sure® Microarrays—Screen all 24 chromosomes to optimize selection of euploid embryos during IVF—and help improve success rates

• VeriSeq™ PGS Solution—Access our widely adopted NGS technology for comprehensive, accurate chromosomal euploid embryo screening and selection

• BlueFuse® Multi analysis software—a multi-user database for storage, analysis, and reporting of results for PGS, PGD, and Cytogenetics

For Research Use Only. Not for use in diagnostic procedures.

Changing reproductive destinies by optimizing embryo selection.

PGD—helping prevent serious gene disorders from being passed on.

PGD offers the powerful ability to screen for two important types of genetic defects. First, it

can identify single-gene genetic conditions, such as cystic fibrosis (CF), sickle-cell anemia, and

certain forms of muscular dystrophy, among others. This can help families avoid passing on

a serious inherited disease to their offspring. PGD is also capable of screening embryos for

chromosomal translocation disorders likely to cause miscarriage. This application may be

especially valuable to couples with a history of miscarriage, which may be related to an

inherited unbalanced translocation.

Our proprietary PGD screening solutions include:

• karyomapping—The most informative, genome-wide, single-cell test available, giving couples at risk of serious inherited diseases a new level of control over their reproductive destinies

• 24sure+™ Microarray—Screen for chromosomal translocations that can cause miscarriage—ensuring only embryos with no overall gain or loss of chromosome segments are transferred

Vy B.—actual PGS patient.

The reassurance of knowing— simply, safely, sooner.

NIPT—reliable answers about fetal chromosomal status, without the risks of invasive procedures.

NIPT represents a major advance in prenatal screening, providing accurate information about

fetal chromosomal status as early as 10 weeks gestation. It can detect the most common fetal

chromosomal aneuploidies, using a single maternal blood draw. In fact, NIPT is proven to be

more accurate than traditional screening methods—even in a general obstetrical population.9

NIPT delivers reliable answers early and

easily, providing parents with the peace

of mind they need to make informed

choices. NIPT also helps reduce the

need for invasive procedures, such as

amniocentesis or chorionic villus

sampling (CVS). This is particularly

meaningful for couples who’ve

undergone fertility treatment.

The reassurance of knowing— simply, safely, sooner.

The verifi® Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. a wholly owned subsidiary of Illumina, Inc. Our laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.

Powered by Illumina. Deeper research, more accurate answers.Using superior technology for informative testing results, our NIPT product offering includes:

• verifi® Prenatal Test—Utilizes massively parallel and whole-genome sequencing to go to greater lengths for accurate answers about the chromosomal status of a developing fetus

– Lowest test failure rate in NIPT10

– Reduced need for blood re-draws

– Clear answers—not “relative risk scores”

– Backed by clinical evidence for increased confidence in test results

– The fastest time to results—as soon as 2 business days from receipt of sample

– Simple, safe and noninvasive—without the risks of more invasive procedures

The verifi® Prenatal Test detects multiple fetal chromosomal aneuploidies including T21

(Down syndrome), T18 (Edwards syndrome), and T13 (Patau syndrome). Wider testing options

for the most common sex aneuploidies and additional chromosomal disorders are also available.

Timely insight into life-changing chromosomal abnormalities.

Cytogenetics—empowering deeper research into the causes of complex disorders.

Chromosomal abnormalities are a common cause of developmental delay and congenital

conditions. These include syndromes, such as Down syndrome, DiGeorge syndrome, and

Cri-Du-Chat syndrome, as well as other rarer microdeletion or microduplication disorders.

Prenatal and postnatal cytogenetic research can allow for further insight into chromosomal

aberrations. Our cytogenetic testing from Illumina provides the highest detection capabilities

for genetic abnormalities. This type of testing takes place prior to conception to detect carrier

status or after birth to identify the presence of genetic conditions early in a child’s life.

Advanced cytogenetic products—for a clearer view of genes.Industry-leading chromosomal microarrays:

• CytoChip™ Arrays—Provide a greater understanding of the relevance and impact of chromosomal aberrations on complex diseases

Innovative technology that uses both sequencing and array scanning:

• Infinium® CytoSNP-850K Beadchip—Offers comprehensive coverage of relevant dosage-sensitive genes for profiling chromosomal abnormalities—providing accurate cytogenetic data and capabilities that exceed standard cytogenetic analyses

– Provides thorough coverage where you need it

– Utilizes a wide variety of sample types, including blood, bone marrow, chorionic villi, and amniotic fluid

– Delivers high-detection sensitivity

– Available on the flexible NextSeq 550 System, capable of performing both NGS and array scanning, and the iScan Array Scanner

For Research Use Only. Not for use in diagnostic procedures.

Timely insight into life-changing chromosomal abnormalities.

Identifying inherited conditions to make a difference for generations.

Detecting undiagnosed inherited conditions—individual answers that affect an entire family.

Some inherited diseases may be immediately obvious at birth, while others may not be. Yet

when such conditions run in a family, you want to be able to make a definitive diagnosis and

provide reliable answers and peace of mind for everyone involved.

Many recessive, pediatric-onset Mendelian disorders are due to pathogenic mutations found

in coding exons and intron-exon boundaries. NGS technology has been successful in finding

causal variants of many such inherited and rare conditions.

Identifying inherited conditions to make a difference for generations.

Recognizing carriers of inherited conditions.

The ability to determine an individual’s carrier status for an inherited condition can be

particularly empowering to a prospective parent concerned about passing on a genetic

disorder. Carrier screening, in conjunction with genetic counseling of carriers, is an effective

way to ensure genetic disease risk is detected early—preferably prior to conception.

NGS expands carrier screening for mutations with potential links to genetic disease.11

Expanded carrier-screening capabilities

• Comprehensive coverage

• Improved detection rates

• The right answers the first time

We currently offer several NGS options to aid in the diagnosis of CF, determine carrier status for

CF, and research other inherited conditions.

For in vitro diagnostic use

• MiSeqDx™ Cystic Fibrosis 139-Variant Assay—The first FDA-cleared NGS assay that can be used to determine CF carrier status

• MiSeqDx Cystic Fibrosis Clinical Sequencing Assay—The first FDA-cleared assay that can be used as an aid in diagnosing CF

• MiSeqDx Universal Kit 1.0—An FDA-cleared sequencing solution enabling clinical labs to develop their own NGS assays for use on the MiSeqDx instrument

For Research Use Only. Not for use in diagnostic procedures.

• TruSight™ Sequencing Panels—Targeted NGS panels focused on specific genes or regions thought to be relevant to particular conditions, including recessive pediatric-onset diseases, autism, and inherited causes of cardiomyopathy

Together, our state-of-the-art assays provide highly accurate results that deliver a deeper

understanding of genetic profiles related to inherited conditions.

Illumina • 1.800.809.4566 toll-free (US) • +1.858.202.4566 tel • techsupport@illumina.com • www.illumina.com

For Research Use Only. Not for use in diagnostic procedures.© 2015 Illumina, Inc. All rights reserved. Illumina, BlueFuse, BlueGnome, CytoChip, EpiGnome, Infinium, MiSeqDx, TruSight, VeriSeq, 24sure, the pumpkin orange color, and the streaming bases design are trademarks of Illumina, Inc. and /or its affiliate(s) in the U.S. and/or other countries. All other names, logos, and other trademarks are the property of their respective owners. Pub. No. 1586-2014-076 Current as of 27 May 2015

• Trusted leader in innovative, accurate genomic technologies

• A comprehensive portfolio of genomic solutions to improve options in reproductive and genetic health

• Timely, reliable answers that empower more informed choices and enhance lives

• Your committed partner for generations to come

Learn more about our comprehensive portfolio of genomic solutions for reproductive and genetic health.

Visit www.illumina.com/rgh

1. SART CORS Clinic Summary Report. SART CORS Web site. www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0. Accessed December 16, 2013.

2. Scott RT Jr, Ferry K, Su J, Tao X, Scott K. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertil Steril. 2012;97(4):870–875.

3. Tobias ES, Connor M, Ferguson-Smith M. Essential medical genetics. 6th edition: pp. 243–247. Chichester, West Sussex, UK. Wiley-Blackwell; 2011.

4. Yang Z, Liu J, Collins GS, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: Results from a randomized pilot study. Mol Cytogenet. 2012;5(1):24.

5. Grifo JA, Hodes-Wertz B, Lee HL, Amperloquio E, Clarke-Williams M, Adler A. Single thawed euploid embryo transfer improves IVF pregnancy, miscarriage, and multiple gestation outcomes and has similar implantation rates as egg donation. J Assist Reprod Genet. 2013;30(2):259–264.

6. Scott RT Jr, Upham KM, Forman EJ, et al. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. Fertil Steril. 2013;100(3):697–703.

7. Forman EJ, Hong KH, Ferry KM, et al. In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. Fertil Steril. 2013;100(1):100–107.

8. Wilton L. Preimplantation genetic diagnosis for aneuploidy screening in early human embryos: a review. Prenat Diagn. 2002:22:512–518.

9. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799–808.

10. Bhatt, et al. Clinical Laboratory Experience with Noninvasive Prenatal Testing: Update on Clinically Relevant Metrics ISPD Data. 2014.

11. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011;3(65):65ra4.

References

Empowering informed choices

in reproductive and genetic health.

A global genomics leader, Illumina delivers complete next-generation sequencing workflow solutions to the

basic and translational research communities. Illumina technology has been calculated to be responsible

for generating more than 90% of the world’s sequencing data. Through collaborative innovation, Illumina

is fueling groundbreaking advancements in the fields of oncology, reproductive health, genetic disease,

microbiology, agriculture, and forensic science.